POSTERS & PRESENTATIONS

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation

2026 Frontiers In Oncology

Estimating the impact of 212Bi demetallation from administration of 212Pb-rhPSMA-10.1 and the risk of significant Kidney Absorbed Radiation Doses

2026 PSMA & Beyond

More Bang For Your Becquerel A Novel Approach to Dosing in 177Lu-PSMA Radioligand Therapy

2025 EANM

Tumour Dosimetry - It's a Grey Area: Analysing the Importance of Lesion Level Dosimetry Methods in 177Lu-PSMA Targeted Therapy

2025 EANM

Modelling absorbed doses to tumors and at-risk organs from a novel PSMA-targeted radioligand labeled with Actinium-225

2025 SNMMI mid-winter meeting

Preclinical evaluation of 225Ac-rhPSMA-10.1, a novel radiohybrid PSMA compound for targeted alpha therapy of prostate cancer

2023 EANM Meeting

Enhanced therapeutic response to 177Lu-rhPSMA-10.1 in pre-clinical models of prostate cancer

2023 SNMMI Meeting

Preclinical evaluation of a novel radioligand therapy for patients with prostate cancer: biodistribution and efficacy of 177Lu-rhPSMA-10.1 in comparison with 177Lu-PSMA-I&T

2022 SNMMI Meeting